Skip to main content
SpringerLink
Log in

Mobilization of Hematopoietic Cells Prior to Autologous or Allogeneic Transplantation

  • Chapter
  • First Online:
Allogeneic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1443 Accesses

Abstract

Several adhesion molecules, including LFA-1, VLA-4, CXCR4, c-kit, CD44, and Mac-1, are known to anchor stem cells to the bone marrow microenvironment, and disruption of the interactions between these adhesion molecules and their ligands by both chemotherapy and cytokines may promote stem and progenitor cell egress into the peripheral circulation. For instance, hematopoietic progenitor cells (HPCs) are mobilized after exposure to antibodies which interrupt the interaction of the β1 integrin VLA-4, expressed on HPCs, and its ligand, VCAM-1, expressed on endothelial and stromal cells [24, 25].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cottler-Fox MH, Lapidot T, Petit I et al. (2003) Stem cell mobilization. Hematology 2003:419-437

    Google Scholar 

  2. Papayannopoulou T, Scadden DT (2008) Stem-cell ecology and stem cells in motion. Blood 111:3923-3930

    PubMed  CAS  Google Scholar 

  3. Goodman JW, Hodgson GS (1962) Evidence for stem cells in the peripheral blood of mice. Blood 19:702-714

    PubMed  CAS  Google Scholar 

  4. Juttner CA, To LB, Haylock DN, Branford A, Kimber RJ (1985) Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 61:739-745

    PubMed  CAS  Google Scholar 

  5. Kessinger A, Armitage JO, Landmark JD, Weisenburger DD (1986) Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 14:192-196

    PubMed  CAS  Google Scholar 

  6. Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM (1986) Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma. Blood 67:529-532

    PubMed  CAS  Google Scholar 

  7. Reiffers J, Bernard P, David B et al (1986) Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 14:312-315

    PubMed  CAS  Google Scholar 

  8. Beyer J, Schwella N, Zingsem J et al (1995) Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 13:1328-1335

    PubMed  CAS  Google Scholar 

  9. Hartmann O, Corroller AGL, Blaise D et al (1997) Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs: A randomized, controlled trial. Ann Intern Med 126:600-607

    PubMed  CAS  Google Scholar 

  10. Smith TJ, Hillner BE, Schmitz N et al (1997) Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. J Clin Oncol 15:5-10

    PubMed  CAS  Google Scholar 

  11. Vose JM, Sharp G, Chan WC et al (2002) Autologous transplantation for aggressive non-Hodgkin’s lymphoma: Results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 20:2344-2352

    PubMed  Google Scholar 

  12. Stem Cell Trialists Collaborative Group (2005) Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J Clin Oncol 23:5074-5087

    Google Scholar 

  13. Bensinger WI, Martin PJ, Storer B et al (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175-181

    PubMed  CAS  Google Scholar 

  14. Blaise D, Kuentz M, Fortanier C et al (2000) Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the societe francaise de greffe de moelle. J Clin Oncol 18:537-546

    PubMed  CAS  Google Scholar 

  15. Couban S, Simpson DR, Barnett MJ et al (2002) A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100:1525-1531

    PubMed  CAS  Google Scholar 

  16. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH (2001) Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 19:3685-3691

    PubMed  CAS  Google Scholar 

  17. Heldal D, Tjonnfjord G, Brinch L et al (2000) A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 25:1129-1136

    PubMed  CAS  Google Scholar 

  18. Powles R, Mehta J, Kulkarni S et al (2000) Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial. Lancet 355:1231-1237

    PubMed  CAS  Google Scholar 

  19. Schmitz N, Beksac M, Hasenclever D et al (2002) Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 100:761-767

    PubMed  CAS  Google Scholar 

  20. Bensinger W, Appelbaum F, Rowley S et al (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555

    PubMed  CAS  Google Scholar 

  21. Desikan K, Barlogie B, Jagannath S et al (1998) Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16:1547-1553

    PubMed  CAS  Google Scholar 

  22. Narayanasami U, Kanteti R, Morelli J et al (2001) Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 98:2059-2064

    PubMed  CAS  Google Scholar 

  23. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C (2000) Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 18:1360-1377

    PubMed  CAS  Google Scholar 

  24. Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T (1997) Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 90:4779-4788

    PubMed  CAS  Google Scholar 

  25. Kikuta T, Shimazaki C, Ashihara E et al (2000) Mobilization of hematopoietic primitive and committed progenitor cells into blood in mice by anti-vascular adhesion molecule-1 antibody alone or in combination with granulocyte colony-stimulating factor. Exp Hematol 28:311-317

    PubMed  CAS  Google Scholar 

  26. Peled A, Petit I, Kollet O et al (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283:845-848

    PubMed  CAS  Google Scholar 

  27. Petit I, Szyper-Kravitz M, Nagler A et al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687-694

    PubMed  CAS  Google Scholar 

  28. King AG, Horowitz D, Dillon SB et al (2001) Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRO{beta}. Blood 97:1534-1542

    PubMed  CAS  Google Scholar 

  29. Pelus LM, Fukuda S (2008) Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia 22:466-473

    PubMed  CAS  Google Scholar 

  30. Liu F, Poursine-Laurent J, Link DC (2000) Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood 95:3025-3031

    PubMed  CAS  Google Scholar 

  31. Fruehauf S, Seggewiss R (2003) It’s moving day: Factors affecting peripheral blood stem mobilization and strategies for improvement. Br J Haematol 122:360-375

    PubMed  CAS  Google Scholar 

  32. Lapidot T, Petit I (2002) Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 30:973-981

    PubMed  CAS  Google Scholar 

  33. Levesque J-P, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ (2001) Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 98:1289-1297

    PubMed  CAS  Google Scholar 

  34. Laterveer L, Lindley I, Hamilton M, Willemze R, Fibbe W (1995) Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood 85:2269-2275

    PubMed  CAS  Google Scholar 

  35. Stackx S, Van den Steen PE, Wuyts A, Van Damme J, Opdenakker G (2002) Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization. Leuk Lymphoma 43:233-241

    Google Scholar 

  36. Pruijt J, Fibbe W, Laterveer L et al (1999) Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci USA 96:10863-10868

    PubMed  CAS  Google Scholar 

  37. Pelus LM, Bian H, King AG, Fukuda S (2004) Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRO{beta}/CXCL2 and GRO{beta}T/CXCL2{Delta}4. Blood 103:110-119

    PubMed  CAS  Google Scholar 

  38. Levesque J-P, Bendall L, Hendy J, Takamatsu Y, Simmons PJ (2002) Neutrophil enzymes degrade CXCR4 on CD34+ progenitors: Implications for progenitor cell mobilization. Blood 100:107a

    Google Scholar 

  39. Papayannopoulou T (2000) Mechanisms of stem-/progenitor-cell mobilization: The anti-VLA-4 paradigm. Semin Hematol 37:11-18

    PubMed  CAS  Google Scholar 

  40. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ (2003) Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111:187-196

    PubMed  CAS  Google Scholar 

  41. Mayack SR, Wagers AJ (2008) Osteolineage niche cells initiate hematopoietic stem cell mobilization. Blood 112:519-531

    PubMed  CAS  Google Scholar 

  42. Christopherson KW II, Hangoc G, Mantel CR, Broxmeyer HE (2004) Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305:1000-1003

    PubMed  CAS  Google Scholar 

  43. Christopherson I, Kent W, Cooper S, Hangoc G, Broxmeyer HE (2003) CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol 31:1126-1134

    PubMed  CAS  Google Scholar 

  44. Christopherson KW II, Cooper S, Broxmeyer HE (2003) Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 101:4680-4686

    PubMed  CAS  Google Scholar 

  45. Levesque J-P, Liu F, Simmons PJ et al (2004) Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 104:65-72

    PubMed  CAS  Google Scholar 

  46. Pruijt J, Verzaal P, Van Os R et al (2002) Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proc Natl Acad Sci USA 99:6228-6233

    PubMed  CAS  Google Scholar 

  47. Semerad CL, Christopher MJ, Liu F et al (2005) G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 106:3020-3027 10.1182/blood-2004-01-0272

    PubMed  CAS  Google Scholar 

  48. Katayama Y, Battista M, Kao WM et al (2006) Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124:407-421

    PubMed  CAS  Google Scholar 

  49. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS (2008) Haematopoietic stem cell release is regulated by circadian oscillations. Nature 452:442-447

    PubMed  CAS  Google Scholar 

  50. Kollet O, Dar A, Lapidot T (2007) The multiple roles of osteoclasts in host defense: Bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol 25:51-69

    PubMed  CAS  Google Scholar 

  51. Kollet O, Dar A, Shivtiel S et al (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12:657-664

    PubMed  CAS  Google Scholar 

  52. Morstyn G, Brown S, Gordon M et al (1994) Stem cell factor is a potent synergistic factor in hematopoiesis. Oncology 51:205-214

    PubMed  CAS  Google Scholar 

  53. Moskowitz CH, Stiff P, Gordon MS et al (1997) Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin’s lymphoma patients - results of a phase I/II trial. Blood 89:3136-3147

    PubMed  CAS  Google Scholar 

  54. Dawson MA, Schwarer AP, Muirhead JL, Bailey MJ, Bollard GM, Spencer A (2005) Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant 36:389-396

    PubMed  CAS  Google Scholar 

  55. Costa JJ, Demetri GD, Harrist TJ et al (1996) Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183:2681-2686

    PubMed  CAS  Google Scholar 

  56. Kopchick JJ, Andry JM (2000) Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab 71:293-314

    PubMed  CAS  Google Scholar 

  57. Merchav S, Tatarsky I, Hochberg Z (1988) Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/somatomedin C and human growth hormone. J Clin Invest 81:791-797

    PubMed  CAS  Google Scholar 

  58. Carlo-Stella C, Di Nicola M, Milani R et al (2004) Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. Exp Hematol 32:171-178

    PubMed  CAS  Google Scholar 

  59. Carlo-Stella C, Di Nicola M, Milani R et al (2004) Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 103:3287-3295

    PubMed  CAS  Google Scholar 

  60. Molineux G, Kinstler O, Briddell B et al (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724-1734

    PubMed  CAS  Google Scholar 

  61. Vose JM, Crump M, Lazarus H et al (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21:514-519

    PubMed  CAS  Google Scholar 

  62. Johnston E, Crawford J, Blackwell S et al (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522-2528

    PubMed  CAS  Google Scholar 

  63. Fruehauf S, Klaus J, Huesing J et al (2007) Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 39:743-750

    PubMed  CAS  Google Scholar 

  64. Russell N, Mesters R, Schubert J et al (2008) A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematologica 93:405-412

    PubMed  CAS  Google Scholar 

  65. Steidl U, Fenk R, Kondalkci M et al (2003) Transplantation of peripheral blood stem cells mobilized by single dose application of pegylated G-CSF in patients with multiple myeloma. Blood 102:3554a

    Google Scholar 

  66. Vadhan-Raj S, Murray LJ, Bueso-Ramos C et al (1997) Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 126:673-681

    PubMed  CAS  Google Scholar 

  67. Linker C, Anderlini P, Herzig R et al (2003) Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant 9:405-413

    PubMed  CAS  Google Scholar 

  68. Calvi LM, Adams GB, Weibrecht KW et al (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841-846

    PubMed  CAS  Google Scholar 

  69. Ballen KK, Shpall EJ, Avigan D et al (2005) Parathyroid hormone may improve autologous stem cell mobilization via the stem cell niche. ASH Ann Meet Abstr 106:1968

    Google Scholar 

  70. Ballen K (2007) Targeting the stem cell niche: Squeezing blood from bones. Bone Marrow Transplant 39:655-660

    PubMed  CAS  Google Scholar 

  71. Pelus LM, Horowitz D, Cooper SC, King AG (2002) Peripheral blood stem cell mobilization: A role for CXC chemokines. Crit Rev Oncol Hematol 43:257-275

    PubMed  Google Scholar 

  72. Hepburn TW, Hart TK, Horton VL et al (2001) Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice. J Pharmacol Exp Ther 298:886-893

    PubMed  CAS  Google Scholar 

  73. De Clercq E (2003) The bicyclam AMD3100 story. Nat Rev 2:581-587

    Google Scholar 

  74. Broxmeyer HE, Orschell CM, Clapp DW et al (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201:1307-1318

    PubMed  CAS  Google Scholar 

  75. Burroughs L, Mielcarek M, Little M-T et al (2005) Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 106:4002-4008 10.1182/blood-2005-05-1937

    PubMed  CAS  Google Scholar 

  76. Larochelle A, Krouse A, Metzger M et al (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107:3772-3778

    PubMed  CAS  Google Scholar 

  77. Steidl U, Kronenwett R, Haas R (2003) Differential gene expression underlying the functional distinctions of primary human CD34+ hematopoietic stem and progenitor cells from peripheral blood and bone marrow. Ann NY Acad Sci 996:89-100

    PubMed  CAS  Google Scholar 

  78. Steidl U, Kronenwett R, Rohr UP et al (2002) Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 99:2037-2044

    PubMed  CAS  Google Scholar 

  79. Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J (2003) Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 102:1249-1253

    PubMed  CAS  Google Scholar 

  80. Hess DA, Bonde J, Craft TP et al (2007) Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 13:398-411

    PubMed  CAS  Google Scholar 

  81. Liles WC, Broxmeyer HE, Rodger E et al (2003) Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102:2728-2730

    PubMed  CAS  Google Scholar 

  82. Liles WC, Rodger E, Broxmeyer HE et al (2005) Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 45:295-300

    PubMed  CAS  Google Scholar 

  83. Devine SM, Flomenberg N, Vesole DH et al (2004) Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol 22:1095-1102

    PubMed  CAS  Google Scholar 

  84. Flomenberg N, Devine SM, DiPersio JF et al (2005) The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106:1867-1874 10.1182/blood-2005-02-0468

    PubMed  CAS  Google Scholar 

  85. Cashen A, Devine S, Vij R, DiPersio J (2005) AMD3100 + G-CSF improves hematopoietic progenitor cell (HPC) collection in patients with Hodgkin’s disease (HD). Blood 106:1979

    Google Scholar 

  86. DiPersio J, Stadtmauer EA, Nademanee AP et al (2007) A Phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor) + G-CSF vs. G-CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Ann Meet Abstr 110:445

    Google Scholar 

  87. DiPersio JF, Micallef I, Stiff PJ et al (2007) A Phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor) + G-CSF vs. placebo + G-CSF in non-Hodgkin’s lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Ann Meet Abstr 110:601

    Google Scholar 

  88. Calandra G, McCarty J, McGuirk J et al (2008) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow Transplant 41:331-338

    PubMed  CAS  Google Scholar 

  89. Micallef I, Stiff PJ, DiPersio JF et al (2007) Successful stem cell mobilization rescue by AMD3100 (Plerixafor) + G-CSF for patients who failed primary mobilization: Results from the Phase III (3101-NHL) study. ASH Ann Meet Abstr 110:602

    Google Scholar 

  90. Weaver CH, Tauer K, Zhen B et al (1998) Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 7:241-249

    PubMed  CAS  Google Scholar 

  91. Perea G, Sureda A, Martino R et al (2001) Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 80:592-597

    PubMed  CAS  Google Scholar 

  92. Gazitt Y, Liu Q (2001) Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin’s lymphoma patients. Stem Cells 19:37-45

    PubMed  CAS  Google Scholar 

  93. Gazitt Y, Shaughnessy P, Liu Q (2001) Expression of adhesion molecules on CD34(+) cells in peripheral blood of non-Hodgkin’s lymphoma patients mobilized with different growth factors. Stem Cells 19:134-143

    PubMed  CAS  Google Scholar 

  94. Benboubker L, Watier H, Carion A et al (2001) Association between the SDF1-3’A allele and high levels of CD34(+) progenitor cells mobilized into peripheral blood in humans. Br J Haematol 113:247-250

    PubMed  CAS  Google Scholar 

  95. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD (2000) Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 18:43-53

    PubMed  CAS  Google Scholar 

  96. Shpall EJ (1999) The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 23(Suppl 2):S13-S19

    Google Scholar 

  97. Stiff P, Gingrich R, Luger S et al (2000) A randomized phase 2 study of PBSC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transplant 26:471-481

    PubMed  CAS  Google Scholar 

  98. Weaver CH, Hazelton B, Birch R et al (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969

    PubMed  CAS  Google Scholar 

  99. Fallon P, Gentry T, Balber AE et al (2003) Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol 122:99-108

    PubMed  Google Scholar 

  100. Hess DA, Meyerrose TE, Wirthlin L et al (2004) Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 104:1648-1655

    PubMed  CAS  Google Scholar 

  101. Shpall EJ, Wheeler CA, Turner SA et al (1999) A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 93:2491-2501

    PubMed  CAS  Google Scholar 

  102. Condomines M, Quittet P, Lu Z-Y et al (2006) Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol 176:6631-6639

    PubMed  CAS  Google Scholar 

  103. Vigorito AC, Marques Junior JF, Aranha FJ, Oliveira GB, Miranda EC, De Souza CA (2001) A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: An update. Haematologica 86:665-666

    PubMed  CAS  Google Scholar 

  104. Eapen M, Logan BR, Confer DL et al (2007) Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 13:1461-1468

    PubMed  Google Scholar 

  105. Heimfeld S (2003) Bone marrow transplantation: How important is CD34 cell dose in HLA-identical stem cell transplantation? Leukemia 17:856-858

    PubMed  CAS  Google Scholar 

  106. Korbling M, Anderlini P (2001) Peripheral blood stem cell versus bone marrow allotransplantation: Does the source of hematopoietic stem cells matter? Blood 98:2900-2908

    PubMed  CAS  Google Scholar 

  107. Mohty M, Bilger K, Jourdan E et al (2003) Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 17:869-875

    PubMed  CAS  Google Scholar 

  108. Przepiorka D, Smith TL, Folloder J et al (1999) Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 94:1465-1470

    PubMed  CAS  Google Scholar 

  109. Zaucha JM, Gooley T, Bensinger WI et al (2001) CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98:3221-3227 10.1182/blood.V98.12.3221

    PubMed  CAS  Google Scholar 

  110. Devine S, Brown R, Mathews V et al (2005) Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplant 36:531-538

    PubMed  CAS  Google Scholar 

  111. Kared H, Leforban B, Montandon R et al (2008) Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood 112:2575-2578

    PubMed  CAS  Google Scholar 

  112. Fischmeister G, Kurz M, Haas OA et al (1999) G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: Comparison of efficacy and tolerability. Ann Hematol 78:117-123

    PubMed  CAS  Google Scholar 

  113. Korbling M, Huh Y, Durett A et al (1995) Allogeneic blood stem cell transplantation: Peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy- 1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86:2842-2848

    PubMed  CAS  Google Scholar 

  114. Anderlini P, Przepiorka D, Seong C et al (1997) Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 37:507-512

    PubMed  CAS  Google Scholar 

  115. Grigg A, Roberts A, Raunow H et al (1995) Optimizing dose and scheduling of filgrastim (granulocyte colony- stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers [see comments]. Blood 86:4437-4445

    PubMed  CAS  Google Scholar 

  116. Holm M (1998) Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J Hematother 7:111-113

    PubMed  CAS  Google Scholar 

  117. Lysak D, Koza V, Jindra P (2005) Factors affecting PBSC mobilization and collection in healthy donors. Transfus Apher Sci 33:275-283

    PubMed  Google Scholar 

  118. Suzuya H, Watanabe T, Nakagawa R et al (2005) Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 89:229-235

    PubMed  CAS  Google Scholar 

  119. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM (2001) Peripheral blood stem cell donation: An analysis from the international bone marrow transplant registry (IBMTR) and european group for blood and marrow transplant (EBMT) databases. Bone Marrow Transplant 27:689-692

    PubMed  CAS  Google Scholar 

  120. de la Rubia J, Arbona C, de Arriba F et al (2002) Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 42:4-9

    PubMed  Google Scholar 

  121. Anderlini P, Przepiorka D, Champlin R, Korbling M (1996) Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 88:2819-2825

    PubMed  CAS  Google Scholar 

  122. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C (2000) Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95:2484-2490

    PubMed  CAS  Google Scholar 

  123. Liu Y-J, Blom B (2000) Introduction: TH2-inducing DC2 for immunotherapy. Blood 95:2482-2483

    PubMed  CAS  Google Scholar 

  124. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL (1995) Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422-4429

    PubMed  CAS  Google Scholar 

  125. Pulendran B, Banchereau J, Burkeholder S et al (2000) Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 165:566-572

    PubMed  CAS  Google Scholar 

  126. Reddy V (2000) Granulocyte colony-stimulating factor mobilization alters dendritic cell cytokine production and initiates T helper 2 polarization prior to host alloantigen presentation. Blood 96:2635

    PubMed  CAS  Google Scholar 

  127. Rondelli D, Raspadori D, Anasetti C et al (1998) Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 22:631-637

    PubMed  CAS  Google Scholar 

  128. Vasconcelos ZFM, dos Santos BM, Farache J et al (2006) G-CSF-treated granulocytes inhibit acute graft-versus-host disease. Blood 107:2192-2199

    PubMed  CAS  Google Scholar 

  129. Hill GR, Morris ES, Fuery M et al (2006) Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 12:603-607

    PubMed  Google Scholar 

  130. MacDonald KPA, Rowe V, Filippich C et al (2003) Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood 101:2033-2042

    PubMed  CAS  Google Scholar 

  131. Morris ES, MacDonald KPA, Hill GR (2006) Stem cell mobilization with G-CSF analogs: A rational approach to separate GVHD and GVL? Blood 107:3430-3435

    PubMed  CAS  Google Scholar 

  132. Anderlini P, Champlin RE (2008) Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: Recent findings and current challenges. Blood 111:1767-1772

    PubMed  CAS  Google Scholar 

  133. Fortanier C, Kuentz M, Sutton L et al (2002) Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: Results of a randomised study. Bone Marrow Transplant 29:145-149

    PubMed  CAS  Google Scholar 

  134. Murata M, Harada M, Kato S et al (1999) Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors. Bone Marrow Transplant 24:1065-1071

    PubMed  CAS  Google Scholar 

  135. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR (2001) Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 97:2541-2548 10.1182/blood.V97.9.2541

    PubMed  CAS  Google Scholar 

  136. Anderlini P, Przepiorka D, Korbling M, Champlin R (1998) Blood stem cell procurement: Donor safety issues. Bone Marrow Transplant 21:S35-S39

    Google Scholar 

  137. Stroncek D, Shawker T, Follmann D, Leitman SF (2003) G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 43:609-613

    PubMed  CAS  Google Scholar 

  138. Platzbecker U, Prange-Krex G, Bornhauser M et al (2001) Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 41:184-189

    PubMed  CAS  Google Scholar 

  139. Stroncek D, Dittmar K, Shawker T, Heatherman A, Leitman S (2004) Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2:25

    PubMed  Google Scholar 

  140. Falzetti F, Aversa F, Minelli O, Tabilio A (1999) Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. The Lancet 353:555

    CAS  Google Scholar 

  141. Becker P, Wagle M, Matous S et al (1997) Spontaneous plenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood and Marrow Transplant 3:45-49

    CAS  Google Scholar 

  142. Kröger N, Renges H, Sonnenberg S et al (2002) Stem cell mobilisation with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 29:727-730

    PubMed  Google Scholar 

  143. Dincer AP, Gottschall J, Margolis DA (2004) Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 26:761-763

    PubMed  Google Scholar 

  144. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J (2004) Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 44:1260-1261

    PubMed  Google Scholar 

  145. de la Rubia J, Martínez C, Solano C et al (1999) Administration of recombinant human granulocyte colony-stimulating factor to normal donors: Results of the Spanish national donor registry. Bone Marrow Transplant 24:723-728

    PubMed  Google Scholar 

  146. Dagia NM, Gadhoum SZ, Knoblauch CA et al (2006) G-CSF induces E-selectin ligand expression on human myeloid cells. Nat Med 12:1185-1190

    PubMed  CAS  Google Scholar 

  147. Fukumoto Y, Miyamoto T, Okamura T et al (1997) Angina pectoris occurring during granulocyte colony-stimulating factor-combined preparatory regimen for autologous peripheral blood stem cell transplantation in a patient with acute myelogenous leukaemia. Br J Haematol 97:666-668

    PubMed  CAS  Google Scholar 

  148. Hill JM, Syed MA, Arai AE et al (2005) Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 46:1643-1648

    PubMed  CAS  Google Scholar 

  149. Lindemann A, Rumberger B (1993) Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF). Eur J Cancer 29:2338-2339

    Google Scholar 

  150. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VVB, Prchal JT (2001) Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97:3313-3314

    PubMed  CAS  Google Scholar 

  151. Horowitz MM, Confer DL (2005) Evaluation of hematopoietic stem cell donors. Hematology 2005:469-475

    Google Scholar 

  152. Kang EM, Areman EM, David-Ocampo V et al (2002) Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 99:850-855

    PubMed  CAS  Google Scholar 

  153. Burt RK, Fassas A, Snowden J et al (2001) Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 28:1-12

    PubMed  CAS  Google Scholar 

  154. Gottenberg JE, Roux S, Desmoulins F, Clerc D, Mariette X (2001) Granulocyte colony-stimulating factor therapy resulting in a flare of systemic lupus erythematosus: Comment on the article by Yang and Hamilton. Arthritis Rheum 44:2458-2460

    PubMed  CAS  Google Scholar 

  155. Nash RA, Bowen JD, McSweeney PA et al (2003) High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102:2364-2372

    PubMed  CAS  Google Scholar 

  156. Stricker RB, Goldberg B (1996) G-CSF and exacerbation of rheumatoid arthritis. Am J Med 100:665-666

    PubMed  CAS  Google Scholar 

  157. Mahmud N, Devine SM, Weller KP et al (2001) The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood 97:3061-3068

    PubMed  CAS  Google Scholar 

  158. Hernandez JM, Castilla C, Gutierrez NC et al (2005) Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 19:1088-1091

    PubMed  CAS  Google Scholar 

  159. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L (2004) Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 32:122-130

    PubMed  CAS  Google Scholar 

  160. Pamphilon D, Mackinnon S, Nacheva E et al (2006) The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant 38:699-700

    PubMed  CAS  Google Scholar 

  161. Bennett CL, Evens AM, Andritsos LA et al (2006) Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: Report from the research on adverse drug events and reports (RADAR) project. Br J Haematol 135:642-650

    PubMed  CAS  Google Scholar 

  162. Makita K, Ohta K, Mugitani A et al (2004) Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 33:661-665

    PubMed  CAS  Google Scholar 

  163. Hasenclever D, Sextro M (1996) Safety of AlloPBPCT donors: Biometrical considerations on monitoring long term risks. Bone Marrow Transplant 17(Suppl 2):S28-S30

    Google Scholar 

  164. Rauscher GH, Sandler DP, Poole C et al (2002) Family history of cancer and incidence of acute leukemia in adults. Am J Epidemiol 156:517-526

    PubMed  Google Scholar 

  165. Shpilberg O, Modan M, Modan B, Chetrit A, Fuchs Z, Ramot B (1994) Familial aggregation of haematological neoplasms: A controlled study. Br J Haematol 87:75-80

    PubMed  CAS  Google Scholar 

  166. Pulsipher MA, Nagler A, Iannone R, Nelson RM (2006) Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 46:422-433

    PubMed  Google Scholar 

  167. Devine SM, Vij R, Rettig M et al (2008) Rapid mobilization of functional donor hematopoietic cells without G-CSF using plerixafor, an antagonist of the CXCR4/SDF-1 interaction. Blood 112:990-998

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology & Oncology, The Ohio State University Medical Center, Columbus, OH, USA

    Steven M. Devine

Authors
  1. Steven M. Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospitals Case Medical Center, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Devine, S.M. (2010). Mobilization of Hematopoietic Cells Prior to Autologous or Allogeneic Transplantation. In: Lazarus, H.M., Laughlin, M.J. (eds) Allogeneic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-478-0_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-478-0_22

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-33-6

  • Online ISBN: 978-1-59745-478-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation